Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Hepatology

• Publication date

  2008-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jhep.2008.05.008PMID 18554744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies.

  2008cited by this paper
• Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

  2008cited by this paper
• Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein

  2007cited by this paper
• Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

  2007cited by this paper
• Is reduction of viral fitness a valid antiviral approach

  2007cited by this paper
• Human Serum Facilitates Hepatitis C Virus Infection, and Neutralizing Responses Inversely Correlate with Viral Replication Kinetics at the Acute Phase of Hepatitis C Virus Infection

  2005cited by this paper
• Diverging Effects of Human Recombinant Anti-Hepatitis C Virus (HCV) Antibody Fragments Derived from a Single Patient on the Infectivity of a Vesicular Stomatitis Virus/HCV Pseudotype

  2002cited by this paper
• Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell–free virions from blood plasma

  1999cited by this paper

• Digital modeling by biomedical informatics analysis predicts suppression of COVID-19 infectivity via ‘targeting oligonucleotide-directed devolution’

  2025cites this paper
• Role of artificial intelligence in peptide vaccine design against RNA viruses

  2021cites this paper
• Molecular and bioinformatic strategies in reducing the burden of influenza infections in slum areas of Dhaka

  2018cites this paper
• Virus-induced preferential antibody gene-usage and its importance in humoral autoimmunity.

  2015cites this paper
• Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infections.

  2015cites this paper
• Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein

  2015cites this paper
• Peptide Vaccine: Progress and Challenges

  2014cites this paper
• Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy.

  2014cites this paper
• Update on the Development of Anti-Viral Agents Against Hepatitis C

  2013cites this paper
• Human Monoclonal Antibodies as a New Class of Antiinfective Compounds

  2013cites this paper
• Oral antiviral therapies for chronic hepatitis C infection

  2013cites this paper
• JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?

  2013cites this paper
• Peptide-Based Vaccinology: Experimental and Computational Approaches to Target Hypervariable Viruses through the Fine Characterization of Protective Epitopes Recognized by Monoclonal Antibodies and the Identification of T-Cell-Activating Peptides

  2013cites this paper
• Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections

  2013cites this paper
• Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein.

  2012cites this paper
• Neutralization Interfering Antibodies: A “Novel” Example of Humoral Immune Dysfunction Facilitating Viral Escape?

  2012cites this paper
• Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference.

  2012cites this paper
• Influenza B-cells Protective Epitope Characterization: A Passkey for the Rational Design of New Broad-Range Anti-Influenza Vaccines

  2012cites this paper
• Phage Display-based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed against Human Pathogens

  2012cites this paper
• Molecular Signatures of Hepatitis C Virus (HCV)-Induced Type II Mixed Cryoglobulinemia (MCII)

  2012cites this paper
• New therapeutic options for HCV infection in the monoclonal antibody era.

  2012influential citation
• Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis.

  2012cites this paper
• A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments.

  2012cites this paper
• HEPATITIS C VIRUS INFECTION IN LIVER TRANSPLANT PATIENTS.

  2012cites this paper
• A Human Monoclonal Antibody with Neutralizing Activity against Highly Divergent Influenza Subtypes

  2011cites this paper
• Potential treatment options and future research to increase hepatitis C virus treatment response rate

  2010cites this paper
• Long-Lasting Protective Antiviral Immunity Induced by Passive Immunotherapies Requires both Neutralizing and Effector Functions of the Administered Monoclonal Antibody

  2010cites this paper
• Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance.

  2010cites this paper
• Hepatitis C virus experimental model systems and antiviral drug research

  2010cites this paper
• Three decades of human monoclonal antibodies: Past, present and future developments

  2009cites this paper
• Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension.

  2009cites this paper
• The hepatitis C virus enigma

  2009cites this paper